Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Daiichi Sankyo : Announces Update to H5N1 Influenza Vaccine National Project

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2019 | 09:19am EDT

Tokyo - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the Company has been unable to fulfill its obligation to build a scheme to supply vaccines for 40 million people in the time allotted under the Japanese Ministry of Health, Labour and Welfare's cell culture vaccine production facility capacity building project, which is a part of the Ministry's second initiative for H5NI vaccine development and production capacity building grant.

After being selected for the project, Daiichi Sankyo had been engaged in preparations to build a scheme to supply vaccines from August 2011 to March 31, 2019.

Daiichi Sankyo and its Group company, Kitasato Daiichi Sankyo Vaccine Co., Ltd., which was dissolved after its functions were transferred to Daiichi Sankyo or its Group company, Daiichi Sankyo Biotech Co., Ltd. (hereafter, Daiichi Sankyo Biotech) on April 1, 2019, reported in April 2014 that they were unable to achieve the original goal of creating a scheme by March 31, 2014, to supply the vaccines for 40 million people in six months. It was discovered in the development phase that higher doses are needed than expected when designing facilities, and they have addressed to increase the vaccination yield and improve the facilities. However, they have been unable to build a scheme capable of supplying vaccines for 40 million people in 6 months by March 31, 2019, the extended time limit for the initiative, and the scheme built is now capable of supplying vaccines for approximately 23 million people. Daiichi Sankyo sincerely apologizes for having been unable to build the required scheme in the timeframe allotted.

In addition to returning a part of the grant, Daiichi Sankyo Biotech will pay a delinquency charge.Daiichi Sankyo believes that assumed delinquency charges have been recorded in the previous fiscal years, and have minor impact on Daiichi Sankyo consolidated profit and loss in the fiscal year ending March 31, 2020.

Daiichi Sankyo and Daiichi Sankyo Biotech will make efforts toward maintaining and managing a scheme that will be fully capable of supplying the required quantity of H5NI influenza vaccine necessary for when a pandemic breaks out, and will contribute to the health of people in Japan.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a 'Global Pharma Innovator with Competitive Advantage in Oncology,' Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.

Contact:

Tel: +81-3-6225-1126

Web: https://www.daiichisankyo.com

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
06/26GENERAL ELECTRIC : Daiichi Sankyo to transfer marketing authorization rights for..
AQ
06/24DAIICHI SANKYO : Provides Update on FDA Review of Quizartinib for the Treatment ..
AQ
06/19DAIICHI SANKYO : VANFLYTA Receives Approval in Japan for the Treatment of Relaps..
AQ
06/17DAIICHI SANKYO : Integral Molecular reaches milestone in I-O target discovery co..
AQ
05/24DAIICHI SANKYO : Announcement Regarding Recent Media Reports
AQ
05/23DAIICHI SANKYO : looking to sell OTC drug unit for about $900 million - Nikkei B..
RE
05/20DAIICHI SANKYO : Announces Update to H5N1 Influenza Vaccine National Project
AQ
05/17DAIICHI SANKYO : FDA advisory panel votes against Daiichi Sankyos quizartinib
AQ
05/16DAIICHI SANKYO : FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiich..
AQ
05/15DAIICHI SANKYO : Precision NanoSystems Signs License Agreement with Daiichi Sank..
AQ
More news
Financials (JPY)
Sales 2020 947 B
EBIT 2020 110 B
Net income 2020 81 093 M
Finance 2020 603 B
Yield 2020 1,15%
P/E ratio 2020 48,8x
P/E ratio 2021 49,0x
EV / Sales2020 3,52x
EV / Sales2021 3,35x
Capitalization 3 939 B
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
DAIICHI SANKYO COMPANY, LIMITED Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DAIICHI SANKYO COMPANY, LI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 6 675,00  JPY
Last Close Price 6 080,00  JPY
Spread / Highest target 43,1%
Spread / Average Target 9,79%
Spread / Lowest Target -9,54%
EPS Revisions
Managers
NameTitle
Joji Nakayama Chairman & CEO
Sunao Manabe President, COO & Representative Director
Toshiaki Sai CFO, Representative Director & Vice President
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Katsumi Fujimoto Director & Senior Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED77.52%35 496
JOHNSON & JOHNSON4.07%372 000
PFIZER-2.86%238 617
ROCHE HOLDING LTD.8.57%233 930
ROCHE HOLDING10.11%233 930
MERCK AND COMPANY5.95%208 546